Compare Moderna, Inc. (MRNA) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs UBS Group AG Registered Ordinary Shares — how do they compare? Moderna, Inc. trades at $195.5 (market cap $78.44B), while UBS Group AG Registered Ordinary Shares trades at $47.72 (market cap $144.63B). The key difference: UBS Group AG Registered Ordinary Shares is the larger of the two by market cap, and UBS Group AG Registered Ordinary Shares pays a 2.32% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.
| MRNA | UBS | |
|---|---|---|
Market Cap | $78.44B | $144.63B |
Volume | 14,597,511 | 1,746,723 |
Sector | Health | Financials |
52-Week High | $203.46 | $55.72 |
52-Week Low | $22.36 | $36.41 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $74.59B | $311.50B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
